Dr. Sud Agarwal
Bio
Dr. Sud Agarwal is an accomplished physician and entrepreneur with extensive experience in the fields of medicinal cannabis and psychedelic therapies.
Stories (5)
Filter by community
A Silent Crisis in Cancer Care: Dr. Sud Agarwal on the Future of Breakthrough Cancer Pain
In cancer care, few symptoms strike more suddenly or more cruelly than breakthrough cancer pain (BTcP). These sharp, transient flares erupt without warning, often piercing through a patient’s otherwise well-managed pain regimen. They’re intense, short-lived, and for many, deeply destabilizing.
By Dr. Sud Agarwal7 months ago in FYI
Rethinking ADHD Research: A Clinical Perspective from Dr. Sud Agarwal, CEO of iNGENū CRO
At just 12 years old, Maya had already cycled through multiple therapists and two medications. She was intelligent, imaginative, and highly curious, but often labeled as distracted and disruptive. Her teachers marked her as a problem student. Her doctors saw a checklist of symptoms. But no one saw the full picture.
By Dr. Sud Agarwal7 months ago in FYI
Neuropathic Pain: A Roadmap to Better Treatments - Insights from Dr. Sud Agarwal and iNGENŪ CRO
Neuropathic pain, a complex and often debilitating condition, presents a significant challenge to both patients and healthcare providers. The International Classification of Diseases (ICD-11) defines pain as arising from damage or disease affecting the somatosensory nervous system, manifesting as sensory disturbances like electric, burning, or shock-like sensations. Unlike nociceptive pain resulting from tissue injury, this type of pain stems from malfunctioning in the nervous system itself.
By Dr. Sud Agarwal9 months ago in FYI
Dr. Sud Agarwal’s Predictions for Industry
The life sciences industry is entering 2025 in an environment of heightened financial pressure, geopolitical shifts, and evolving regulatory landscapes. As the CEO of a CRO deeply engaged in global clinical research, Dr. Sud observed several key trends that will shape industry-sponsored research this year. From funding constraints in biotech to rising patient costs and the strong U.S. dollar’s impact, sponsors and CROs alike will need to adapt rapidly. Here’s my perspective on the critical challenges and opportunities ahead.
By Dr. Sud Agarwal11 months ago in FYI
Dr. Sud Agarwal and Darryl Davies on IRX211 – A Breakthrough in Managing Breakthrough Cancer Pain (BTcP)
Introduction Breakthrough cancer pain (BTcP) is a sudden and severe pain episode that interrupts the background pain relief provided by long-acting analgesics. Historically, immediate-acting fentanyl-based drugs such as Abstral or Fentora (fentanyl buccal tablets) and Actiq (fentanyl lozenges) were widely used for BTcP. These treatments demonstrated significant pain relief in clinical trials, but their withdrawal due to safety concerns and misuse potential has left patients with no approved BTcP-specific therapies.
By Dr. Sud Agarwal12 months ago in FYI
